Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
60 studies found for:    Open Studies | "Hemorrhagic Fevers, Viral"
Show Display Options
RSS Create an RSS feed from your search for:
Open Studies | "Hemorrhagic Fevers, Viral"
Need help? See RSS Feeds
Choose a feed type:
Show studies first received on any dateShow studies that were first received in the last 14 days
Show studies last updated date on any dateShow studies that were added or modified in the last 14 days
Rank Status Study
1 Recruiting Phase 2a Immunogenicity Study of Hantaan/Puumala Virus DNA Vaccine for Prevention of Hemorrhagic Fever
Condition: Hemorrhagic Fever With Renal Syndrome
Interventions: Biological: HTNV/PUUV DNA vaccine;   Biological: Placebo
2 Not yet recruiting Intravenous Ribavirin Protocol to Treat Individuals With Viral Hemorrhagic Fever
Condition: Viral Hemorrhagic Fever
Intervention: Drug: Ribavirin
3 Recruiting Long-term Safety Follow-up of Participants Exposed to the Candidate Ebola Vaccines Ad26.ZEBOV and/or MVA-BN-Filo
Condition: Hemorrhagic Fever, Ebola
Interventions: Biological: Ad26.ZEBOV;   Biological: MVA-BN-Filo
4 Recruiting Safety, Tolerability and Immunogenicity Study of 2 Prime-boost Regimens for Ebola Vaccines Ad26.ZEBOV/MVA-BN-Filo
Condition: Hemorrhagic Fever, Ebola
Interventions: Biological: Ad26.ZEBOV;   Biological: MVA-BN-Filo;   Biological: Placebo
5 Recruiting Safety, Tolerability and Immunogenicity Study of 3 Prime-boost Regimens for Ebola Vaccines Ad26.ZEBOV/MVA-BN-Filo in Healthy Adults, Children and Human Immunodeficiency Virus Positive (HIV+) Adults
Condition: Hemorrhagic Fever, Ebola
Interventions: Biological: Ad26.ZEBOV;   Biological: MVA-BN-Filo;   Biological: Placebo
6 Not yet recruiting Open Study of the Duration of Immunity After Vaccination With GamEvac
Condition: Hemorrhagic Fever, Ebola
Intervention: Procedure: blood sampling collection
7 Not yet recruiting Open Study of the Duration of Immunity After Vaccination With GamEvac-Combi
Condition: Ebola Hemorrhagic Fever
Intervention: Procedure: blood sampling collection
8 Recruiting Immunogenicity and Safety of a Tetravalent Dengue Vaccine Booster Injection in Subjects Who Previously Completed a 3-dose Schedule
Conditions: Dengue Fever;   Dengue Hemorrhagic Fever
Interventions: Biological: CYD Dengue Vaccine (5 dose formulation);   Biological: Placebo, NaCl 0.9%
9 Not yet recruiting Safety and Immunogenicity of a Tetravalent Dengue Vaccine in HIV-Positive Adults
Conditions: Dengue Fever;   Dengue Hemorrhagic Fever;   Human Immunodeficiency Virus
Interventions: Biological: CYD Dengue Vaccine;   Biological: Placebo (NaCl 0.9%) vaccine group
10 Recruiting Study of a Booster Dose of a Tetravalent Dengue Vaccine in Subjects Who Previously Completed the 3-dose Schedule
Conditions: Dengue Fever;   Dengue Hemorrhagic Fever
Interventions: Biological: CYD Dengue Vaccine (5-dose formulation);   Biological: Placebo, NaCl 0.9%
11 Recruiting Diagnostic of Puumala Virus Infection in France
Conditions: Nephropathia Epidemica;   Hemorrhagic Fever With Renal Syndrome
Intervention:
12 Unknown  Chinese and Western Medicine Treatment of Fever Associated With Bleeding Symptoms
Conditions: Viral Haemorrhagic Fever;   Dengue Fever
Interventions: Drug: Western Medicine;   Drug: TCM and Western Medicine
13 Not yet recruiting MVA-BN®-Filo and Ad26.ZEBOV Vaccines in Healthy Volunteers
Conditions: Marburg Disease;   Ebola Disease
Interventions: Biological: MVA Multi-Filo Ebola Vaccine;   Biological: Ad26 Zaire Ebola Vaccine
14 Not yet recruiting Partnership for Research on Ebola VACcinations
Condition: Ebola Virus Disease
Interventions: Biological: Ad26.ZEBOV;   Biological: MVA-BN-Filo;   Biological: rVSVΔG-ZEBOV-GP;   Biological: Placebo;   Biological: rVSV boost
15 Recruiting GS-5734 to Assess the Antiviral Activity, Longer-Term Clearance of Ebola Virus, and Safety in Male Ebola Survivors With Evidence of Ebola Virus Persistence in Semen
Condition: Persistent Ebola Virus
Interventions: Drug: GS-5734;   Other: Placebo Comparator
16 Recruiting Tolerance and Activity Evaluation of High Doses of Favipiravir Against Ebola Virus in the Semen
Condition: Ebola Virus Survivor
Intervention: Drug: Favipiravir
17 Recruiting Ebola Virus Disease Survivors: Clinical and Immunologic Follow-up
Condition: Ebola Virus Disease
Intervention:
18 Not yet recruiting Multiple Treatments for Ebola Virus Disease (EVD)
Condition: Ebola Virus Disease
Interventions: Drug: Azithromycin;   Drug: Sunitinib and Erlotinib;   Drug: Atorvastatin and Irbesartan;   Other: IV fluids and laboratory testing
19 Recruiting Clinical Trial to Evaluate the Efficacy and Safety of Convalescent Plasma for Ebola Treatment
Condition: Ebola Virus Disease
Intervention: Procedure: Convalescent Plasma Treatment
20 Recruiting A Study to Assess New Ebola Vaccines, cAd3-EBO Z and MVA-BN® Filo
Conditions: Ebola;   Ebola Zaire
Interventions: Biological: cAd3-EBO Z at 1 x 10^10 vp;   Biological: cAd3-EBO Z at 2.5 x 10^10 vp;   Biological: cAd3-EBO Z at 5 x 10^10 vp;   Biological: 4.4x10^8 TCID50s MVA-BN® Filo;   Biological: 2.2x10^8 TCID50s MVA-BN® Filo;   Biological: 4.4 x 10^7 TCID50s MVA-BN® Filo

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years